KPTI: Karyopharm Therapeutics Net earnings per share for the last 12 months

Symbol and logo of brand Karyopharm Therapeutics, Inc. (KPTI)

Karyopharm Therapeutics (KPTI) is accelerating the launch of oncology drugs through a partnership with Menarini. The TTM annual earnings per share illustrates the market response, where -14.13 becomes the new value for this metric. Amid margin constraints driven by marketing expenses and geopolitical risks affecting component logistics and patent protection, Karyopharm Therapeutics is striving for the global expansion of its therapy.

KPTI (Karyopharm Therapeutics) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/18/2026

Analytical breakdowns for Karyopharm Therapeutics

Basic company analysis:karyopharm.com - KPTI
Manufactured products of Karyopharm Therapeutics, Inc.

For Karyopharm Therapeutics (KPTI), the trailing twelve-month earnings per share serves as an indicator of real profit generation efficiency. This metric calculates the net funds remaining per share over 12 months, neutralizing temporary fluctuations and the effect of capital dilution. This calculation demonstrates the business's ability to convert market share into actual shareholder income. Growth in this indicator confirms the success of the expansion into the myeloma supportive therapy segment. Positive momentum here signifies a steady strengthening of the company's fundamental value.

Who Karyopharm Therapeutics competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (Exelixis Corp)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) enliventherapeutics.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Propanc Biopharma Inc - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGMS|AADI: Net earnings per share for the last 12 months|aileronrx.com - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics Inc. - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics, Inc) - Net earnings per share (EPS TTM)